Market Cap 1.10B
Revenue (ttm) 906.95M
Net Income (ttm) 121.75M
EPS (ttm) N/A
PE Ratio 6.34
Forward PE 6.45
Profit Margin 13.42%
Debt to Equity Ratio 0.42
Volume 99,100
Avg Vol 80,122
Day's Range N/A - N/A
Shares Out 6.75M
Stochastic %K 10%
Beta 1.47
Analysts Hold
Price Target $181.25

Company Profile

Virtus Investment Partners, Inc. is a publicly owned investment manager. The firm primarily provides its services to individual and institutional clients. It launches separate client focused equity and fixed income portfolios. The firm launches equity, fixed income, and balanced mutual funds for its clients. It invests in the public equity, fixed income, and real estate markets. The firm also invests in exchange traded funds. It employs a multi manager approach for its products. The firm employs...

Industry: Asset Management
Sector: Financial Services
Phone: 800-248-7971
Address:
One Financial Plaza, Hartford, United States
ZacksResearch
ZacksResearch Feb. 4 at 6:00 AM
Why $ARES, $VCTR, and $VRTS are poised for Q4 beats! 📈 These asset managers boast a potent combo of positive Earnings ESP and a Zacks Rank #3 (Hold) or better, suggesting a strong chance of surpassing estimates. ARES is projected to see a 39% EPS rise, while VCTR has a 14.5% expected growth. VRTS may face a decline but remains a strong contender in a rapidly growing industry. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2828180/3-asset-management-stocks-set-to-pull-off-earnings-beat-in-q4?cid=sm-stocktwits-2-2828180-body-31742&ADID=SYND_STOCKTWITS_TWEET_2_2828180_BODY_31742
0 · Reply
DoughCook
DoughCook Feb. 4 at 3:57 AM
$VRTS ( Virtus Investment Partners, Inc.) has completed a Bearish Head and Shoulders pattern on the 3-month chart. Price broke below the neckline, confirming a loss of upward momentum after the right shoulder failed. The breakdown, paired with expanding sell volume, signals increasing bearish pressure in the near term.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 29 at 11:22 PM
$LXRX Sorry, got the tickers wrong, not $VRTS, $VRTX = Journavx. Viatris is our amazing 'partner'. I got the tickers wrong, not the message. Get a dog: @blaack_rules
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 29 at 11:11 PM
$LXRX $VRTS = Journavx Topline was shit in December of 2024. $VRTS fell like a rock in December. And was FDA approved literally the following month in January 2025 . Journavx from $VRTS = This was for MODERATE TO Acute pain. ​ Pilavapadin???? from $LXRX = Ours? is for CHRONIC PAIN-THE HIGHEST LEVEL OF PAIN POSSIBLE. I don't recall $VRTS having a 'partner'. This is an easy $LXRX slam dunk. You bitch to much about 'partners'. Get a dog, you'll have a nice 'partner'. Partner starved trader.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 24 at 5:13 AM
$VRTS Current Stock Price: $165.68
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 6:22 PM
$LXRX Super interesting long term study on Heart, Diabetes growth: THIS IS LITERALLY THE ENTIRE ARTICLE = "A study released Jan. 12 by the Journal of the American College of Cardiology analyzed the current state of heart health in the U.S., highlighting the burden of disease, quality of care and mortality trends of risk factors and conditions that can lead to heart disease. The study found no change in the prevalence of hypertension among U.S. adults from 2009-2023 but found that hypertension-related cardiovascular deaths nearly doubled from 23 per 100,000 in 2000 to 43 per 100,000 in 2019. The prevalence of diabetes in U.S. adults increased from 11.9% in 2009-2010 to 14.1% in 2021-2023. Deaths related to type 2 diabetes increased from 30.4 per 100,000 adults in 2009 to 54 per 100,000 adults in 2023. The study analyzed other risk factors and conditions such as obesity, cigarette smoking and stroke, among others." https://www.aha.org/news/headline/2026-01-13-study-analyzes-state-us-heart-health-and-risk-factors $VRTS $NVO $IBB $BIB
0 · Reply
DoughCook
DoughCook Jan. 11 at 8:33 PM
$VRTS — Buyers kept stepping in higher while sellers stalled. Ascending triangle breaks as price pushes through the ceiling.
0 · Reply
DonCorleone77
DonCorleone77 Dec. 23 at 10:52 AM
$VRTS Virtus Investment price target lowered to $218 from $225 at Piper Sandler Piper Sandler analyst Crispin Love lowered the firm's price target on Virtus Investment to $218 from $225 and keeps an Overweight rating on the shares as part of a Q4 preview for the asset management group. Deal activity has begun to recover, but private credit has dominated headlines as investors worry about a potential surge in defaults, the analyst tells investors in a research note. Piper believes the concerns are overstated, saying fundamentals are "solid" with loan- to-value ratios in the 30%-40% range, "providing substantial cushion against losses."
0 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 10:28 AM
Piper Sandler updates rating for Virtus Inv ( $VRTS ) to Overweight, target set at 225 → 218.
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 5:45 PM
Morgan Stanley has updated their rating for Virtus Inv ( $VRTS ) to Underweight with a price target of 168.
0 · Reply
Latest News on VRTS
Virtus Introduces Virtus Silvant Growth Opportunities ETF

Dec 23, 2025, 4:10 PM EST - 6 weeks ago

Virtus Introduces Virtus Silvant Growth Opportunities ETF


Four Virtus Closed-End Funds Add Portfolio Manager

Sep 26, 2025, 9:00 AM EDT - 4 months ago

Four Virtus Closed-End Funds Add Portfolio Manager


Virtus Introduces Virtus AlphaSimplex Global Macro ETF

Aug 5, 2025, 9:00 AM EDT - 6 months ago

Virtus Introduces Virtus AlphaSimplex Global Macro ETF

ASGM


Virtus Introduces Virtus Seix AAA Private Credit CLO ETF

Dec 3, 2024, 9:00 AM EST - 1 year ago

Virtus Introduces Virtus Seix AAA Private Credit CLO ETF

PCLO


Virtus Introduces Virtus KAR Mid-Cap ETF

Oct 16, 2024, 3:00 PM EDT - 1 year ago

Virtus Introduces Virtus KAR Mid-Cap ETF


ZacksResearch
ZacksResearch Feb. 4 at 6:00 AM
Why $ARES, $VCTR, and $VRTS are poised for Q4 beats! 📈 These asset managers boast a potent combo of positive Earnings ESP and a Zacks Rank #3 (Hold) or better, suggesting a strong chance of surpassing estimates. ARES is projected to see a 39% EPS rise, while VCTR has a 14.5% expected growth. VRTS may face a decline but remains a strong contender in a rapidly growing industry. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2828180/3-asset-management-stocks-set-to-pull-off-earnings-beat-in-q4?cid=sm-stocktwits-2-2828180-body-31742&ADID=SYND_STOCKTWITS_TWEET_2_2828180_BODY_31742
0 · Reply
DoughCook
DoughCook Feb. 4 at 3:57 AM
$VRTS ( Virtus Investment Partners, Inc.) has completed a Bearish Head and Shoulders pattern on the 3-month chart. Price broke below the neckline, confirming a loss of upward momentum after the right shoulder failed. The breakdown, paired with expanding sell volume, signals increasing bearish pressure in the near term.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 29 at 11:22 PM
$LXRX Sorry, got the tickers wrong, not $VRTS, $VRTX = Journavx. Viatris is our amazing 'partner'. I got the tickers wrong, not the message. Get a dog: @blaack_rules
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 29 at 11:11 PM
$LXRX $VRTS = Journavx Topline was shit in December of 2024. $VRTS fell like a rock in December. And was FDA approved literally the following month in January 2025 . Journavx from $VRTS = This was for MODERATE TO Acute pain. ​ Pilavapadin???? from $LXRX = Ours? is for CHRONIC PAIN-THE HIGHEST LEVEL OF PAIN POSSIBLE. I don't recall $VRTS having a 'partner'. This is an easy $LXRX slam dunk. You bitch to much about 'partners'. Get a dog, you'll have a nice 'partner'. Partner starved trader.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 24 at 5:13 AM
$VRTS Current Stock Price: $165.68
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 6:22 PM
$LXRX Super interesting long term study on Heart, Diabetes growth: THIS IS LITERALLY THE ENTIRE ARTICLE = "A study released Jan. 12 by the Journal of the American College of Cardiology analyzed the current state of heart health in the U.S., highlighting the burden of disease, quality of care and mortality trends of risk factors and conditions that can lead to heart disease. The study found no change in the prevalence of hypertension among U.S. adults from 2009-2023 but found that hypertension-related cardiovascular deaths nearly doubled from 23 per 100,000 in 2000 to 43 per 100,000 in 2019. The prevalence of diabetes in U.S. adults increased from 11.9% in 2009-2010 to 14.1% in 2021-2023. Deaths related to type 2 diabetes increased from 30.4 per 100,000 adults in 2009 to 54 per 100,000 adults in 2023. The study analyzed other risk factors and conditions such as obesity, cigarette smoking and stroke, among others." https://www.aha.org/news/headline/2026-01-13-study-analyzes-state-us-heart-health-and-risk-factors $VRTS $NVO $IBB $BIB
0 · Reply
DoughCook
DoughCook Jan. 11 at 8:33 PM
$VRTS — Buyers kept stepping in higher while sellers stalled. Ascending triangle breaks as price pushes through the ceiling.
0 · Reply
DonCorleone77
DonCorleone77 Dec. 23 at 10:52 AM
$VRTS Virtus Investment price target lowered to $218 from $225 at Piper Sandler Piper Sandler analyst Crispin Love lowered the firm's price target on Virtus Investment to $218 from $225 and keeps an Overweight rating on the shares as part of a Q4 preview for the asset management group. Deal activity has begun to recover, but private credit has dominated headlines as investors worry about a potential surge in defaults, the analyst tells investors in a research note. Piper believes the concerns are overstated, saying fundamentals are "solid" with loan- to-value ratios in the 30%-40% range, "providing substantial cushion against losses."
0 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 10:28 AM
Piper Sandler updates rating for Virtus Inv ( $VRTS ) to Overweight, target set at 225 → 218.
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 5:45 PM
Morgan Stanley has updated their rating for Virtus Inv ( $VRTS ) to Underweight with a price target of 168.
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 8:34 PM
Barclays has adjusted their stance on Virtus Inv ( $VRTS ), setting the rating to Underweight with a target price of 175 → 158.
0 · Reply
ZacksResearch
ZacksResearch Dec. 8 at 5:27 PM
Big move from $VRTS — stepping straight into private markets. They’re taking a majority stake in Keystone to bolt on asset-backed lending capabilities, a clear push to expand beyond traditional asset management. Full breakdown here 👉 https://www.zacks.com/stock/news/2801167/virtus-pushes-into-private-markets-with-majority-stake-in-keystone?cid=sm-stocktwits-2-2801167-teaser-23853&ADID=SYND_STOCKTWITS_TWEET_2_2801167_TEASER_23853
0 · Reply
ZacksResearch
ZacksResearch Dec. 8 at 4:27 PM
$VRTS is betting big on private credit! 💼 Virtus's acquisition of a majority stake in Keystone involves $200M at closing and up to an additional $170M in deferred consideration. The deal aims to boost its multi-manager model, with the deal expected to be accretive to earnings in 2026. This move positions VRTS to capitalize on the rising demand for private market solutions. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2801167/virtus-pushes-into-private-markets-with-majority-stake-in-keystone?cid=sm-stocktwits-2-2801167-body-23855&ADID=SYND_STOCKTWITS_TWEET_2_2801167_BODY_23855
0 · Reply
slowgrind
slowgrind Nov. 12 at 3:29 PM
$VRTS SOLD.
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 12 at 4:14 AM
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 5:31 PM
Morgan Stanley has updated their rating for Virtus Inv ( $VRTS ) to Underweight with a price target of 170.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 12:05 PM
Barclays has adjusted their stance on Virtus Inv ( $VRTS ), setting the rating to Underweight with a target price of 190 → 175.
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 13 at 2:06 PM
$VRTS Current Stock Price: $186.52 No options data available.
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 8 at 11:21 AM
$VRTS Current Stock Price: $190.90 No options data available.
0 · Reply
Whiskey1679
Whiskey1679 Oct. 2 at 6:46 PM
BAKKT ( BKKT ) Stock is Skyrocketing Thursday: What's Going On? 12:45 PM EDT, October 02, 2025 (Benzinga Newswire) $BKKT 12:45 PM EDT, October 02, 2025 (Benzinga Newswire) Bakkt Holdings Inc (NYSE:BKKT) shares are trading higher, lifted by a broader crypto market rally and recent strategic restructuring. Here’s what investors need to know. What To Know: On Wednesday, the company finalized the sale of its loyalty business, cementing what the company calls its transformation into a pure-play digital asset platform. This move, aimed at lowering costs and sharpening focus, follows the Sept. 22 appointment of fintech veteran Mike Alfred to its board, further signaling its commitment to core crypto services. The stock’s rise Thursday is tied to Bitcoin’s (CRYPTO: BTC) strength, which is being partly attributed to the ongoing U.S. government shutdown. Movers & Shakers: $ASTS $RKLB $RKT $VRTS
0 · Reply
Okadarlan
Okadarlan Sep. 26 at 8:14 PM
$VRTS went through multiple outcomes and its likely to go to 110-120 zone mid 2026.
0 · Reply
Okadarlan
Okadarlan Sep. 26 at 8:02 PM
$VRTS 138
0 · Reply